Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

NCT02594215 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

NIH

Sponsor class

Conditions

Proteus Syndrome

Interventions

DRUG: MK-7075 (miransertib)

Sponsor

National Human Genome Research Institute (NHGRI)